Pure Care Inc

purecareinc.com

Canada's primary supplier of quality Physiotherapy, Chiropractic and other rehabilitation products. Pure Care was founded in 1997 by it's previous president Rick Haughton, and grew to be Canada's number 1 quality rehabilitation product supplier. In 2007 the company was sold to new shareholders and under the current CEO has expended to 3 strategic warehouse locations and 3 central customer service locations.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

MISSION BIO ANNOUNCES PHARMA ASSAY DEVELOPMENT SERVICES FOR SOLID TUMOR RESEARCH

Mission Bio | July 18, 2022

news image

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the launch of solid tumor assays through its Pharma Assay Development (PAD) services. The availability of this new service offering will help to accelerate the development of cancer therapeutics by reducing the time and cost associated with the characterization of solid tumor cells. Precision therapeutics for solid tumors have been historically bottlenecked due to technical challe...

Read More

CELL AND GENE THERAPY

BICYCLE THERAPEUTICS ANNOUNCES CONTINUED CLINICAL PROGRESS AND UPDATES TO MANAGEMENT TEAM

Bicycle Therapeutics | January 06, 2022

news image

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced continued progress in its ongoing Phase I/II clinical trials of BT8009, BT5528 and BT7480. “Last quarter, we reported interim clinical results from ongoing trials of two of our Bicycle toxin conjugates, BT8009 and BT5528, demonstrating preliminary anti-tumor activity in tw...

Read More

CELL AND GENE THERAPY

SHORELINE BIOSCIENCES ANNOUNCES $140M FINANCING TO ADVANCE PIPELINE OF NEXT GENERATION CELL IMMUNOTHERAPIES

Shoreline Biosciences | November 02, 2021

news image

Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem cells (iPSC) derived natural killer (NK) and macrophage cellular immunotherapies, today announced the completion of a $140M financing, led by Ally Bridge Group, with participation from new investors Eventide Asset Management, BeiGene, Irving Investors, Kingdon, NS Investment, Piper Heartland Healthcare Capital, and Supers...

Read More

MEDICAL

ZYNEX RECOGNIZED AS FOURTH LARGEST BIOTECHNOLOGY/BIOSCIENCE COMPANY IN COLORADO

Zynex, Inc. | March 24, 2022

news image

Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the Denver Business Journal has recognized Zynex as the fourth largest Biotechnology/Bioscience public company in Colorado based on number of companywide employees as of November 1, 2021. 2021 was a strong year for us with growth on the top and ...

Read More
news image

CELL AND GENE THERAPY

MISSION BIO ANNOUNCES PHARMA ASSAY DEVELOPMENT SERVICES FOR SOLID TUMOR RESEARCH

Mission Bio | July 18, 2022

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the launch of solid tumor assays through its Pharma Assay Development (PAD) services. The availability of this new service offering will help to accelerate the development of cancer therapeutics by reducing the time and cost associated with the characterization of solid tumor cells. Precision therapeutics for solid tumors have been historically bottlenecked due to technical challe...

Read More
news image

CELL AND GENE THERAPY

BICYCLE THERAPEUTICS ANNOUNCES CONTINUED CLINICAL PROGRESS AND UPDATES TO MANAGEMENT TEAM

Bicycle Therapeutics | January 06, 2022

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced continued progress in its ongoing Phase I/II clinical trials of BT8009, BT5528 and BT7480. “Last quarter, we reported interim clinical results from ongoing trials of two of our Bicycle toxin conjugates, BT8009 and BT5528, demonstrating preliminary anti-tumor activity in tw...

Read More
news image

CELL AND GENE THERAPY

SHORELINE BIOSCIENCES ANNOUNCES $140M FINANCING TO ADVANCE PIPELINE OF NEXT GENERATION CELL IMMUNOTHERAPIES

Shoreline Biosciences | November 02, 2021

Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem cells (iPSC) derived natural killer (NK) and macrophage cellular immunotherapies, today announced the completion of a $140M financing, led by Ally Bridge Group, with participation from new investors Eventide Asset Management, BeiGene, Irving Investors, Kingdon, NS Investment, Piper Heartland Healthcare Capital, and Supers...

Read More
news image

MEDICAL

ZYNEX RECOGNIZED AS FOURTH LARGEST BIOTECHNOLOGY/BIOSCIENCE COMPANY IN COLORADO

Zynex, Inc. | March 24, 2022

Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the Denver Business Journal has recognized Zynex as the fourth largest Biotechnology/Bioscience public company in Colorado based on number of companywide employees as of November 1, 2021. 2021 was a strong year for us with growth on the top and ...

Read More